1. Scrip
  2. >>R&D
  3. >>Clinical Trials

CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure

Anti-Amyloid Debate Continues With Mixed Readouts

 
• By Mandy Jackson

Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody. 

Brain image on blue background
Lecanemab's efficacy may hinge on the type of amyloid it clears from the brain • Source: Shutterstock

All eyes will be on the first presentation of detailed results for Eisai Co., Ltd./Biogen, Inc.’s amyloid-clearing antibody lecanemab from the Phase III Clarity AD trial at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting from 29 November to 2 December in San Francisco. But data for other anti-amyloid therapies also may shed some light on what could make lecanemab stand out as it nears approval and launch.

Following Roche Holding AG’s announcement on 14 November that its anti-amyloid antibody gantenerumab failed to significantly best placebo in the Phase III GRADUATE I and GRADUATE II trials, lecanemab’s positive readout will be the star of the show with its CTAD-opening presentation on 29 November

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.